How to assess the effectiveness of nasal influenza vaccines? Role and measurement of sIgA in mucosal secretions

Influenza Other Respir Viruses. 2019 Sep;13(5):429-437. doi: 10.1111/irv.12664. Epub 2019 Jun 21.

Abstract

Secretory IgAs (sIgA) constitute the principal isotype of antibodies present in nasal and mucosal secretions. They are secreted by plasma cells adjacent to the mucosal epithelial cells, the site where infection occurs, and are the main humoral mediator of mucosal immunity. Mucosally delivered vaccines, such as live attenuated influenza vaccine (LAIV), are able to mimic natural infection without causing disease or virus transmission and mainly elicit a local immune response. The measurement of sIgA concentrations in nasal swab/wash and saliva samples is therefore a valuable tool for evaluating their role in the effectiveness of such vaccines. Here, we describe two standardized assays (enzyme-linked immunosorbent assay and microneutralization) available for the quantification of sIgA and discuss the advantages and limitations of their use.

Keywords: enzyme-linked immunosorbent assay; influenza vaccines; influenza virus; mucosal immunity; secretory IgAs.

Publication types

  • Review

MeSH terms

  • Administration, Intranasal
  • Antibodies, Viral / analysis*
  • Enzyme-Linked Immunosorbent Assay*
  • Humans
  • Immunity, Mucosal
  • Immunoglobulin A, Secretory / analysis*
  • Influenza Vaccines / immunology*
  • Mucus / immunology
  • Neutralization Tests*
  • Vaccines, Attenuated / immunology
  • Vaccines, Inactivated / immunology

Substances

  • Antibodies, Viral
  • Immunoglobulin A, Secretory
  • Influenza Vaccines
  • Vaccines, Attenuated
  • Vaccines, Inactivated